Richard A. Guarino, M.D.
Oxford Pharmaceutical Services Inc.
OXFORD PHARMACEUTICAL SERVICES
ACQUIRES MARPLAN® (isocarboxazid) FROM HOFFMANN-LA ROCHE
Nutley, NJ and Clifton, NJ – October, 1998 – Hoffmann-La Roche Inc.
and Oxford Pharmaceutical Services Inc.
, announced today that Oxford is acquiring ownership of the NDA for the antidepressant product Marplan ® (isocarboxazid) from Roche.
Oxford will assume sales, marketing and distribution of Marplan ® November 13, 1998.
Orders for Marplan ® should be directed to Oxford Pharmaceutical Services, Inc.
, 1 US Highway 46 West, Totowa, NJ 07512.
Questions or requests for prescribing information on Marplan ® should be addressed to Dr. Richard Guarino
- telephone number 973-256-0600, fax number 973-837-0572, e-mail email@example.com.
Marplan®, a monoamine oxidase (MAO) inhibitor, is indicated as a second-line treatment for depression.
"Marplan ® is an important option for patients who are unresponsive to other antidepressants such as: SSRIs or traditional antidepressants like amitriptyline.
Marplan ® has shown significant efficacy in treating depression, and, for certain patients, may offer relief from depression that they otherwise might not be able to achieve," said Richard A. Guarino, M.D., President of Oxford.
"We’re delighted to be able to offer this medication for sale once again," said Guarino